10 09, 2020

@10xGenomics buys @CARTANAbio for in situ GX analysis validation

By | September 10th, 2020|Categories: 10X Genomics, Methods and applications, Next-generation sequencing, Single-cell sequencing|0 Comments

CARTANA in situ sequencing was just bought by 10X Genomics for $41.2 million. They provide a complement to the Visium technology that generates beautiful gene expression maps of tissue sections as seen in Fig 1c of a recent bioRxiv report (see below). The method was […]

4 08, 2020

UK COVID diagnostics from @nanopore and @DNANudge

By | August 4th, 2020|Categories: Diagnostics Tech, Methods and applications, Nanopore sequencing, Next-generation sequencing|0 Comments

The UK biotech sector was in the news yesterday morning with two companies and their COVID tests making headlines: Oxford Nanopore and DNANudge. Both are offering rapid testing for COVID-19 in the NHS and in care homes (where they are desperately needed). There is only […]

30 07, 2020

Happy 6th birthday $1000 genome…

By | July 30th, 2020|Categories: Epigenomics, Next-generation sequencing, Other stuff|3 Comments

When I wrote the post about the $1000 genome’s upcoming 5th birthday last Summer I was hoping the Moore’s Law genome graph would restart it’s downward trajectory. That has not happened according to todays look at their graphic. I’m beginning to wonder how long we’ll […]

28 02, 2020

The biggest sequencer on the block – @MGI_BGI DNBSEQ Tx

By | February 28th, 2020|Categories: Next-generation sequencing|Tags: , |0 Comments

The announcement of the first $100 30x human genome (reagents only) from Rade Drmanac in the final slot at #AGBT20 means that@MGI_BGI’s DNBSeq Tx is going to be the biggest sequencer in the world. However. it remains to be seen if the $100 genome will be an […]

27 11, 2019

Evidence for the use of cfDNA Fragmentome for early detection and monitoring of cacner

By | November 27th, 2019|Categories: Diagnostics Tech, Methods and applications, Next-generation sequencing|0 Comments

In Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection researchers at the Institute of Human Genetics in Austria demonstrate the use of cfDNA for cancer detection and monitoring. The group performed deep ATAC-Seq and deep cfDNA nucleosome mapping to […]

31 10, 2019

CMA says no to @illumina @pacbio deal

By | October 31st, 2019|Categories: Next-generation sequencing|11 Comments

October 25th was my birthday so I’ve been on holiday and waited till I got back before writing this post. There’s been lots of other coverage e.g. GenomeWeb, Motley Fool. Keith at OmicsOmics included a bit more on the other NGS players and emerging technologies and is worth […]

8 10, 2019

@Illumina and @Qiagen’s IVD deal: what does it mean for NGS?

By | October 8th, 2019|Categories: Next-generation sequencing, Uncategorized|1 Comment

Yesterday Illumina and Qiagen announced a 15 year deal to partner on development of NGS in vitro diagnostic kits to run on Illumina sequencers. And Qiagen, more quietly, announced that development of the GeneReader platform will cease. The second piece of news is unsurprising; I’d written about Qiagens […]

11 06, 2019

Will the $1000 genome celebrate its 5th birthday?

By | June 11th, 2019|Categories: Next-generation sequencing|13 Comments

Everyone who has read this blog more than once has seen the Moore’s Law slide below (at a meeting, online, in a book, in a TED talk…). Many times this has come from the NHGRI who have tracked sequencing costs for yonks. Their costs presented […]

6 06, 2019

2-color SBS: @MGI_BGI vs @Illumina

By | June 6th, 2019|Categories: Next-generation sequencing|3 Comments

Updates in […] following some feedback and comments! MGI and Illumina are going head-to-head in a patent battle over the chemistry used to sequence genomes. The battle for sequencing supremacy was won many years ago by Illumina (although @nanopore,@MGI_BGI and a few others still in stealth […]

Load More Posts